Literature DB >> 16364742

Viral persistence: parameters, mechanisms and future predictions.

Michael B A Oldstone1.   

Abstract

For a virus to persist, it must actively curtail the host's antiviral immune response. Here, we review the conceptual basis by which this can occur and discuss the subsequent fate of differentiated cells infected over long periods of time. We also consider how the compromised antiviral immune response can be revigorated or replaced with a potent response that purges the virus and thereby terminates persistent infection.

Entities:  

Mesh:

Year:  2006        PMID: 16364742     DOI: 10.1016/j.virol.2005.09.028

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  38 in total

1.  Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery.

Authors:  Shaobo Han; Ayuna Asoyan; Hannah Rabenstein; Naoko Nakano; Reinhard Obst
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

2.  An intermediate dose of LCMV clone 13 causes prolonged morbidity that is maintained by CD4+ T cells.

Authors:  Andrew Stamm; Laura Valentine; Rashaun Potts; Mary Premenko-Lanier
Journal:  Virology       Date:  2012-02-04       Impact factor: 3.616

3.  Genomic and biological characterization of aggressive and docile strains of lymphocytic choriomeningitis virus rescued from a plasmid-based reverse-genetics system.

Authors:  Minjie Chen; Shuiyun Lan; Rong Ou; Graeme E Price; Hong Jiang; Juan Carlos de la Torre; Demetrius Moskophidis
Journal:  J Gen Virol       Date:  2008-06       Impact factor: 3.891

Review 4.  Keeping it in check: chronic viral infection and antiviral immunity in the brain.

Authors:  Katelyn D Miller; Matthias J Schnell; Glenn F Rall
Journal:  Nat Rev Neurosci       Date:  2016-11-04       Impact factor: 34.870

5.  Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy.

Authors:  C S Coffin; P M Mulrooney-Cousins; M G Peters; G van Marle; J P Roberts; T I Michalak; N A Terrault
Journal:  J Viral Hepat       Date:  2011-06       Impact factor: 3.728

6.  Expanded potential for recombinant trisegmented lymphocytic choriomeningitis viruses: protein production, antibody production, and in vivo assessment of biological function of genes of interest.

Authors:  Daniel L Popkin; John R Teijaro; Andrew M Lee; Hanna Lewicki; Sebastien Emonet; Juan Carlos de la Torre; Michael Oldstone
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

7.  Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections.

Authors:  Elina I Zuniga; Li-Ying Liou; Lauren Mack; Marilyn Mendoza; Michael B A Oldstone
Journal:  Cell Host Microbe       Date:  2008-10-16       Impact factor: 21.023

8.  Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection.

Authors:  Kevin B Walsh; David Marsolais; Megan J Welch; Hugh Rosen; Michael B A Oldstone
Journal:  Virology       Date:  2009-12-03       Impact factor: 3.616

9.  Lymphocytic choriomeningitis virus infection yields overlapping CD4+ and CD8+ T-cell responses.

Authors:  Courtney Dow; Carla Oseroff; Bjoern Peters; Courtney Nance-Sotelo; John Sidney; Michael Buchmeier; Alessandro Sette; Bianca R Mothé
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

10.  Induction of dendritic cell production of type I and type III interferons by wild-type and vaccine strains of measles virus: role of defective interfering RNAs.

Authors:  Rupak Shivakoti; Martina Siwek; Debra Hauer; Kimberly L W Schultz; Diane E Griffin
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.